Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy

Status Recruiting

Clinical Trial Summary

Multicentre Study of nomacopan in Paediatric Haematopoietic Stem-Cell Transplant Associated Thrombotic Microangiopathy

Clinical Trial Description

This is an open-label, multi-centre study of two-parts, Part A and B, includes 24 weeks of treatment, safety follow up after 30 days. Part A: dose algorithm, safety and efficacy Part B: safety and efficacy ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04784455
Study type	Interventional
Source	AKARI Therapeutics
Contact	Wynne W Davies, MD
Phone	02080040268
Email	medical.monitors@akaritx.com
Status	Recruiting
Phase	Phase 3
Start date	February 1, 2021
Completion date	December 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04098445` - TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
Recruiting	`NCT03605511` - TTP and aHUS in Complicated Pregnancies
Not yet recruiting	`NCT05996679` - Automated Surveillance, Alert, and Rapid Diagnosis of Thrombotic Microangiopathies: the ASARD-TMA Study
Completed	`NCT02222545` - Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies	Phase 2
Recruiting	`NCT06102694` - Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy
Completed	`NCT03252925` - A Safety and Efficacy Study of NAC in Patients With TA-TMA	Phase 3
Not yet recruiting	`NCT06182410` - Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma	Phase 2
Recruiting	`NCT05855083` - Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA	Phase 2
Completed	`NCT03384693` - Defibrotide TMA Prophylaxis Pilot Trial	Phase 2
Not yet recruiting	`NCT05702996` - Multicenter, Uncontrolled Pilot Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic Microangiopathies	Phase 3
Not yet recruiting	`NCT02373267` - Screening of TMA Patients für ADAMTS13 Activity (Adamscreen)	N/A
Recruiting	`NCT06098378` - Study of Patients With Thrombotic Microangiopathy Associated With Mitomycin C, Treated or Not With Eculizumab
Completed	`NCT02134171` - Early Predictive Factors of Cardiac and Cerebral Involvement in TMA	N/A
Withdrawn	`NCT04970004` - Study in Adult and Pediatric Patients With HSCT-TMA
Recruiting	`NCT03205995` - Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome	Phase 3
Active, not recruiting	`NCT04570397` - Ravulizumab and COVID-19	Phase 3
Recruiting	`NCT05634928` - Construction of a Database for TMA
Completed	`NCT03518203` - Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients	Phase 2
Recruiting	`NCT04745195` - Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium
Recruiting	`NCT06291415` - The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)	Phase 1